glp-1 diarrhea legal team in west virginia class action Addressing patient concerns about the 'newness' and long GLP-1 Receptor Agonists in Obese
Description
GLP-2 is an epithelial growth factor implicated in epithelial homeostasis, barrier function, and repair following injury
Here is how GLP-1 options compare, according to clinical trials: Daily oral semaglutide (Wegovy): Average weight loss of 13.6 percent of body weight after about 15 months of treatment, compared with 2.2 percent in a placebo group Average weight loss of 11.2 percent of body weight after 72 weeks of treatment, compared with 2.1 percent in the placebo group
S.HueyE
Zhang, H., Zhang, X., Hu, C
Why Switch
[DOI] [PMC free article] [PubMed] [Google Scholar] Moore A
